HONG KONG, GERMANTOWN, Md. and?SUZHOU, China, June 14, 2023 /PRNewswire/ --? Sirnaomics Ltd.(the "Company"; stock code: 2257, together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics,?today announced that the...
HONG KONG, GERMANTOWN,?Md. and SUZHOU,?China, June 5, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Company", Stock Code: 2257.HK, together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced the in...
HONG KONG,?Germantown, Md. and Suzhou, China, June 2, 2023 /PRNewswire/ -- Sirnaomics?Ltd.?(the "Company"; together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today...
HONG KONG and?GERMANTOWN, Md. and SUZHOU BIOBAY, China, May 17, 2023 /PRNewswire/ --?Sirnaomics?Ltd.?(the "Company"; together with its subsidiaries, the"Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeuti...
GERMANTOWN, Md. and GUANGZHOU, China, April 28, 2023 /PRNewswire/ --?RNAimmune, Inc.(the "Company" or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, today announced that the Company has received a clearance from the Uni...
Study commences following green light from the U.S. FDA for Investigational New Drug Application HONG KONG, GERMANTOWN, Md. and SUZHOU, China, April 12, 2023 /PRNewswire/ --? Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the"Group" or "Sirnaomics"), a leadin...
Significant Progress in Clinical Trials for Core Products Reinforces Leading Position in RNA Therapeutics with Strong Product Pipeline Matrix Business Highlights * Clinical development * STP705 -? The part-one Phase IIb interim data on STP705 for the treatment of isSCC was announced, with th...
HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, March 20, 2023 /PRNewswire/ --?Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, and together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company in the discovery and development of advanced RNAi thera...
HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Feb. 7, 2023 /PRNewswire/ --? Sirnaomics Ltd.?(the "Company", Stock Code: 2257.HK, and together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics today announced ...
HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Feb. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd.?(the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that it is advancing the clinical development of...
First three out of five cohorts pass safety requirements, allowing the Company to dose additional cohorts to assess safety, tolerability, pharmacokinetics and anti-tumor activity HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Dec. 21, 2022 /PRNewswire/ -- Sirnaomics Ltd.(Stock Code: 2257.HK) (th...
Dose escalation cohort study is evaluating the safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with isSCC GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 14, 2022 /PRNewswire/ -- Sirnaomics Ltd.?(the "Company" or "Sirnaomics", stock...
GERMANTOWN, Md. and HONG KONG, Dec. 14, 2022 /PRNewswire/ -- Sirnaomics Ltd.?( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...
GERMANTOWN, Md. and HONG KONG, Dec. 13, 2022 /PRNewswire/ -- Sirnaomics Ltd.?( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...
Data results expected to be available in 1H 2023 GAITHERSBURG, Md. and SUZHOU, China, Nov. 8, 2022 /PRNewswire/ --?Sirnaomics Ltd . (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeut...
Sirnaomics Chief Technology Officer Dmitry Samarsky is a featured speaker at the RNA LeadersUSA Congress and 18th Drug Discovery Innovation Programme Gaithersburg, Md. and Suzhou, China, Oct. 19, 2022 /PRNewswire/ --?Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK)?a leading ...
GAITHERSBURG, Md.?and SUZHOU, China, Sept. 20, 2022 /PRNewswire/ --?Sirnaomics Ltd . (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the la...
GAITHERSBURG, Md. and SUZHOU, China, Sept. 7, 2022 /PRNewswire/ --?Sirnaomics Ltd.(the "Company"?or?"Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that Dr.Patrick Lu, PhD, founder, Chairman of the Board, ...
Data showed an excellent safety profile with no adverse events among the five subjects treated. Company continues to explore doses in the ongoing Phase II dose escalation study GAITHERSBURG, Md and SUZHOU, China, Aug. 29, 2022 /PRNewswire/ -- Sirnaomics Ltd.(the "Company"?or?"Sirnaomics", stock ...
GAITHERSBURG, Md. and SUZHOU, China, Aug. 26, 2022 /PRNewswire/ --?Sirnaomics Ltd.?(the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the advancement of its GalAhead? RNAi delivery platform f...